In 747 patients with advanced clear-cell renal cell carcinoma progressing after anti-PD-1/PD-L1 therapy, belzutifan-lenvatinib vs cabozantinib improved median PFS (14·8 vs 10·7 months; HR 0·70) at interim analysis; overall survival was not significantly different (HR 0·85).
RCTn = 747
Motzer et al. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial